SEC Form 4 · accession 0001140361-17-015046
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alicia J. Hager
Officer — SVP & General Counsel
Period of report
Apr 4, 2017
Accepted (ET)
Apr 5, 2017 · 7:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Apr 4, 2017 | S | 32 | $8.8743 | D | 25,845 | D | |
| Common StockF2 | Apr 4, 2017 | S | 4,284 | $9.0582 | D | 21,561 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes.
- F2Includes 12,500 restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.